A detailed history of Centaurus Financial, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Centaurus Financial, Inc. holds 120 shares of REGN stock, worth $85,736. This represents 0.01% of its overall portfolio holdings.

Number of Shares
120
Previous 112 7.14%
Holding current value
$85,736
Previous $117,000 7.69%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1024.09 - $1201.76 $8,192 - $9,614
8 Added 7.14%
120 $126,000
Q2 2024

Sep 20, 2024

BUY
$883.2 - $1071.19 $98,918 - $119,973
112 New
112 $117,000
Q4 2023

Feb 26, 2024

SELL
$775.18 - $881.7 $37,208 - $42,321
-48 Reduced 29.09%
117 $102,000
Q3 2023

Nov 13, 2023

BUY
$692.45 - $844.37 $114,254 - $139,321
165 New
165 $136,000
Q3 2022

Dec 05, 2022

BUY
$573.97 - $724.32 $2,869 - $3,621
5 Added 0.24%
2,112 $1.46 Million
Q2 2022

Aug 02, 2022

BUY
$548.35 - $738.84 $548 - $738
1 Added 0.05%
2,107 $1.25 Million
Q1 2022

May 13, 2022

BUY
$595.12 - $698.43 $13,092 - $15,365
22 Added 1.06%
2,106 $1.47 Million
Q4 2021

Feb 01, 2022

BUY
$543.48 - $670.97 $371,740 - $458,943
684 Added 48.86%
2,084 $1.32 Million
Q3 2021

Nov 12, 2021

BUY
$574.03 - $680.96 $9,184 - $10,895
16 Added 1.16%
1,400 $847,000
Q2 2021

Aug 10, 2021

BUY
$472.8 - $558.54 $654,355 - $773,019
1,384 New
1,384 $773,000
Q2 2019

Aug 15, 2019

SELL
$299.6 - $414.82 $68,908 - $95,408
-230 Closed
0 $0
Q1 2019

Jul 01, 2019

SELL
$372.08 - $439.57 $122,414 - $144,618
-329 Reduced 58.86%
230 $559,000
Q1 2019

May 13, 2019

BUY
$372.08 - $439.57 $207,992 - $245,719
559 New
559 $230,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $76.6B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Centaurus Financial, Inc. Portfolio

Follow Centaurus Financial, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centaurus Financial, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Centaurus Financial, Inc. with notifications on news.